Effects of topical oral G-CSF on chemotherapy induced oral mucositis in cancer patients

口腔粘膜炎是癌症化疗中的剂量限制性毒性。然而，目前，日本还没有建立有效的预防或治疗口腔粘膜炎的病因。在美国和欧洲，化疗引起的粘膜炎事件通过局部口服G-CSF（粒细胞集落刺激因子）治疗。我们报告说，我们已经生产了一种局部口服G-CSF漱口水，并用它来治疗日本癌症患者的口腔粘膜炎。G-CSF（非格司亭）作为漱口水（羧甲基纤维素2%）以4x 75 μ g/天的剂量给药5天，以治疗重度粘膜炎（NCI-CTCAEv 3.0 3级或4级）。结果：严重的口腔黏膜炎明显减少，进食困难和口腔疼痛均得到改善。总之，局部口服G-CSF漱口水可能有助于减少口腔粘膜炎和改善生活质量。

Oral mucositis is a dose-limiting toxicity in cancer chemotherapy. However, at present, no effective causal prophylaxis or treatment for oral mucositis is established in Japan. In USA and Europe, incidents of chemotherapy-induced mucositis was treated by topical oral G-CSF (Granulocyte-colony stimulating factor). We report that we have produced a topical oral G-CSF mouthrinses and used it to treat oral mucositis in Japanese cancer patients. G-CSF (filgrastim) was administered as a mouthrinses (carboxymethylcellulose 2%) at a dose of 4x75ug/day for 5 days against severe mucositis (NCI-CTCAEv3.0 grade 3 or 4). Result: Severe mucositis was reduced significantly and both eating difficulties and oral pain were improved. In conclusion, topical oral G-CSF mouthrinses may be beneficial in reducing oral mucositis and improving the quality of life.